Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.21 Million USD | -432.16% |
| 2022 | -1.54 Million USD | 90.61% |
| 2021 | -16.44 Million USD | -29.96% |
| 2020 | -12.65 Million USD | -363.23% |
| 2019 | -2.73 Million USD | -23.17% |
| 2018 | -2.21 Million USD | -74.47% |
| 2017 | -1.27 Million USD | -32.37% |
| 2016 | -960.19 Thousand USD | 11.76% |
| 2015 | -1.08 Million USD | 31.37% |
| 2014 | -1.58 Million USD | -371.84% |
| 2013 | 583.25 Thousand USD | -39.45% |
| 2012 | 963.22 Thousand USD | 35.72% |
| 2011 | 709.72 Thousand USD | 113.63% |
| 2010 | 332.22 Thousand USD | 198.04% |
| 2009 | -338.87 Thousand USD | -22.48% |
| 2008 | -276.66 Thousand USD | -469.55% |
| 2007 | -48.57 Thousand USD | -139.0% |
| 2006 | 124.55 Thousand USD | -2.21% |
| 2005 | 127.36 Thousand USD | 5.9% |
| 2004 | 120.26 Thousand USD | -34.35% |
| 2003 | 183.18 Thousand USD | 59.09% |
| 2002 | 115.14 Thousand USD | -36.39% |
| 2001 | 181.02 Thousand USD | -12.44% |
| 2000 | 206.74 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.87 Million USD | 180.47% |
| 2024 Q1 | -2.33 Million USD | 71.63% |
| 2023 Q1 | -861.68 Thousand USD | 44.17% |
| 2023 FY | -8.21 Million USD | -432.16% |
| 2023 Q2 | -792.12 Thousand USD | 8.07% |
| 2023 Q4 | -8.21 Million USD | -367.58% |
| 2023 Q3 | -1.75 Million USD | -121.76% |
| 2022 Q3 | -4.28 Million USD | 42.43% |
| 2022 Q4 | -1.54 Million USD | 63.98% |
| 2022 Q1 | -11.78 Million USD | 28.33% |
| 2022 FY | -1.54 Million USD | 90.61% |
| 2022 Q2 | -7.44 Million USD | 36.83% |
| 2021 Q1 | -15.31 Million USD | -21.05% |
| 2021 Q3 | -8.26 Million USD | 26.7% |
| 2021 Q4 | -16.44 Million USD | -98.92% |
| 2021 FY | -16.44 Million USD | -29.96% |
| 2021 Q2 | -11.27 Million USD | 26.37% |
| 2020 Q1 | -884.97 Thousand USD | 67.6% |
| 2020 FY | -12.65 Million USD | -363.23% |
| 2020 Q4 | -12.65 Million USD | -520.53% |
| 2020 Q3 | -2.03 Million USD | -153.14% |
| 2020 Q2 | -805.41 Thousand USD | 8.99% |
| 2019 FY | -2.73 Million USD | -23.17% |
| 2019 Q1 | -1.05 Million USD | 52.61% |
| 2019 Q2 | -6.54 Million USD | -523.01% |
| 2019 Q3 | -4.93 Million USD | 24.58% |
| 2019 Q4 | -2.73 Million USD | 44.69% |
| 2018 Q1 | -609.55 Thousand USD | 52.04% |
| 2018 FY | -2.21 Million USD | -74.47% |
| 2018 Q4 | -2.21 Million USD | -97.57% |
| 2018 Q3 | -1.12 Million USD | 27.17% |
| 2018 Q2 | -1.54 Million USD | -152.81% |
| 2017 FY | -1.27 Million USD | -32.37% |
| 2017 Q4 | -1.27 Million USD | 5.34% |
| 2017 Q3 | -1.34 Million USD | -0.91% |
| 2017 Q2 | -1.33 Million USD | 18.77% |
| 2017 Q1 | -1.63 Million USD | -70.6% |
| 2016 Q4 | -960.19 Thousand USD | -45.09% |
| 2016 Q1 | -370.39 Thousand USD | 65.96% |
| 2016 Q2 | -1.44 Million USD | -290.13% |
| 2016 Q3 | -661.81 Thousand USD | 54.2% |
| 2016 FY | -960.19 Thousand USD | 11.76% |
| 2015 Q4 | -1.08 Million USD | 45.38% |
| 2015 Q1 | -1.06 Million USD | 32.68% |
| 2015 Q2 | -661.65 Thousand USD | 38.02% |
| 2015 FY | -1.08 Million USD | 31.37% |
| 2015 Q3 | -1.99 Million USD | -201.12% |
| 2014 Q2 | -667.91 Thousand USD | -4563.52% |
| 2014 FY | -1.58 Million USD | -371.84% |
| 2014 Q3 | -1.93 Million USD | -189.64% |
| 2014 Q4 | -1.58 Million USD | 18.04% |
| 2014 Q1 | -14.32 Thousand USD | -102.46% |
| 2013 Q2 | 375.22 Thousand USD | -55.88% |
| 2013 Q3 | 364.24 Thousand USD | -2.92% |
| 2013 Q4 | 583.25 Thousand USD | 60.13% |
| 2013 FY | 583.25 Thousand USD | -39.45% |
| 2013 Q1 | 850.4 Thousand USD | -11.71% |
| 2012 Q4 | 963.22 Thousand USD | 22.41% |
| 2012 Q1 | 870.88 Thousand USD | 22.71% |
| 2012 Q2 | 838.8 Thousand USD | -3.68% |
| 2012 FY | 963.22 Thousand USD | 35.72% |
| 2012 Q3 | 786.91 Thousand USD | -6.19% |
| 2011 Q4 | 709.72 Thousand USD | -9.4% |
| 2011 Q3 | 783.33 Thousand USD | 27.87% |
| 2011 Q1 | 411.75 Thousand USD | 23.94% |
| 2011 Q2 | 612.59 Thousand USD | 48.77% |
| 2011 FY | 709.72 Thousand USD | 113.63% |
| 2010 FY | 332.22 Thousand USD | 198.04% |
| 2010 Q2 | -131.49 Thousand USD | 47.8% |
| 2010 Q4 | 332.22 Thousand USD | -22.93% |
| 2010 Q3 | 431.05 Thousand USD | 427.8% |
| 2010 Q1 | -251.92 Thousand USD | 25.66% |
| 2009 Q2 | -239.3 Thousand USD | 8.18% |
| 2009 Q4 | -338.87 Thousand USD | -21.66% |
| 2009 FY | -338.87 Thousand USD | -22.48% |
| 2009 Q1 | -260.62 Thousand USD | 5.8% |
| 2009 Q3 | -278.54 Thousand USD | -16.4% |
| 2008 FY | -276.66 Thousand USD | -469.55% |
| 2008 Q4 | -276.66 Thousand USD | -13.8% |
| 2008 Q3 | -243.12 Thousand USD | -17.66% |
| 2008 Q2 | -206.63 Thousand USD | 23.45% |
| 2008 Q1 | -269.94 Thousand USD | -455.71% |
| 2007 Q2 | 101.92 Thousand USD | -5.48% |
| 2007 Q1 | 107.82 Thousand USD | -13.43% |
| 2007 Q4 | -48.57 Thousand USD | -141.1% |
| 2007 FY | -48.57 Thousand USD | -139.0% |
| 2007 Q3 | 118.18 Thousand USD | 15.95% |
| 2006 Q4 | 124.55 Thousand USD | -8.36% |
| 2006 FY | 124.55 Thousand USD | -2.21% |
| 2006 Q3 | 135.91 Thousand USD | 18.74% |
| 2006 Q2 | 114.47 Thousand USD | -1.51% |
| 2006 Q1 | 116.22 Thousand USD | -8.75% |
| 2005 FY | 127.36 Thousand USD | 5.9% |
| 2005 Q4 | 127.36 Thousand USD | 24.57% |
| 2005 Q1 | 22.79 Thousand USD | -81.04% |
| 2005 Q2 | 143.03 Thousand USD | 527.39% |
| 2005 Q3 | 102.24 Thousand USD | -28.52% |
| 2004 Q1 | 82.09 Thousand USD | -55.18% |
| 2004 Q3 | 83.12 Thousand USD | -35.39% |
| 2004 Q2 | 128.64 Thousand USD | 56.7% |
| 2004 FY | 120.26 Thousand USD | -34.35% |
| 2004 Q4 | 120.26 Thousand USD | 44.69% |
| 2003 Q4 | 183.18 Thousand USD | -9.18% |
| 2003 FY | 183.18 Thousand USD | 59.09% |
| 2003 Q1 | 122.24 Thousand USD | 6.17% |
| 2003 Q2 | 130.06 Thousand USD | 6.39% |
| 2003 Q3 | 201.71 Thousand USD | 55.09% |
| 2002 Q4 | 115.14 Thousand USD | 33.67% |
| 2002 Q1 | 253.96 Thousand USD | 40.29% |
| 2002 FY | 115.14 Thousand USD | -36.39% |
| 2002 Q2 | 138.96 Thousand USD | -45.28% |
| 2002 Q3 | 86.14 Thousand USD | -38.01% |
| 2001 Q4 | 181.02 Thousand USD | -3.2% |
| 2001 Q3 | 187.01 Thousand USD | -3.75% |
| 2001 FY | 181.02 Thousand USD | -12.44% |
| 2001 Q1 | 203.45 Thousand USD | -1.59% |
| 2001 Q2 | 194.29 Thousand USD | -4.5% |
| 2000 Q4 | 206.74 Thousand USD | -10.43% |
| 2000 Q3 | 230.81 Thousand USD | 0.0% |
| 2000 FY | 206.74 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 545.967% |
| Alpha Teknova, Inc. | 1.97 Million USD | 516.083% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 108.719% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 110.959% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.887% |
| Cosmos Health Inc. | 8.59 Million USD | 195.608% |
| Journey Medical Corporation | -9.7 Million USD | 15.403% |
| Embecta Corp. | 1.31 Billion USD | 100.626% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.791% |
| Dynavax Technologies Corporation | 106.63 Million USD | 107.702% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 93.722% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.898% |
| PainReform Ltd. | -7.95 Million USD | -3.314% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 47.466% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 47.466% |
| SCYNEXIS, Inc. | -19.35 Million USD | 57.553% |
| Safety Shot Inc | -2.28 Million USD | -259.55% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 12.898% |
| Procaps Group, S.A. | 242.93 Million USD | 103.381% |
| Theratechnologies Inc. | 24.87 Million USD | 133.024% |
| Harrow Health, Inc. | 116.41 Million USD | 107.055% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -225.932% |
| Biofrontera Inc. | 4.05 Million USD | 302.502% |
| DURECT Corporation | -7.65 Million USD | -7.31% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 75.502% |
| Cronos Group Inc. | -663.32 Million USD | 98.762% |
| OptiNose, Inc. | 58.06 Million USD | 114.145% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 101.318% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 43.635% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -58.377% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 154.709% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -29.15% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 7786.275% |
| Radius Health, Inc. | 359.28 Million USD | 102.286% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 4264.859% |
| ProPhase Labs, Inc. | 19.23 Million USD | 142.71% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.806% |
| Procaps Group S.A. | 242.93 Million USD | 103.381% |
| Alvotech | 1.06 Billion USD | 100.772% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 323.314% |
| Viatris Inc. | 17.13 Billion USD | 100.048% |
| Rockwell Medical, Inc. | 4.45 Million USD | 284.324% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -68.412% |
| SIGA Technologies, Inc. | -148.68 Million USD | 94.476% |
| Tilray Brands, Inc. | 158.97 Million USD | 105.166% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 106.738% |
| Shineco, Inc. | 29.29 Million USD | 128.042% |
| PetIQ, Inc. | 351.93 Million USD | 102.334% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -183.084% |
| Incannex Healthcare Limited | -5.48 Million USD | -49.744% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 104.633% |
| Alimera Sciences, Inc. | 55.3 Million USD | 114.85% |
| Silver Spike Investment Corp. | -32.61 Million USD | 74.814% |
| Assertio Holdings, Inc. | -32.52 Million USD | 74.75% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -451.713% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -62.309% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -70.616% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 294.771% |
| Hempacco Co., Inc. | 13.61 Million USD | 160.328% |
| Talphera, Inc. | -5.72 Million USD | -43.567% |
| Alvotech | 1.06 Billion USD | 100.772% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 214.954% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 91.507% |
| Currenc Group, Inc. | -16.57 Million USD | 50.441% |
| Kamada Ltd. | -46.43 Million USD | 82.311% |
| Indivior PLC | -33.95 Million USD | 75.809% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 3252.071% |
| Flora Growth Corp. | -713 Thousand USD | -1051.96% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -0.0% |
| Evolus, Inc. | 63.7 Million USD | 112.892% |
| HUTCHMED (China) Limited | -197.45 Million USD | 95.84% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.714% |
| Akanda Corp. | 3.9 Million USD | 310.337% |